Biguanide plus thiazolidinedione

This page covers all Biguanide plus thiazolidinedione drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PPAR-γ (pioglitazone component); metformin target not fully elucidated but involves mitochondrial function.

Targets

PPAR-γ (pioglitazone component); metformin target not fully elucidated but involves mitochondrial function

Phase 3 pipeline (1)

• Metformin plus pioglitazone · Nanjing First Hospital, Nanjing Medical University · Diabetes
  Metformin reduces hepatic glucose production and improves insulin sensitivity, while pioglitazone enhances insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ) in adipose and muscle tissue.

Patent intelligence

• biguanide plus thiazolidinedione patent landscape — aggregated cliff calendar, attackable patents, originator estates